Stockscreener 앱 받기
88.22
0.44%
0.39
시간 외 거래:
88.22
전일 마감가:
$87.83
열려 있는:
$87.93
하루 거래량:
422.93K
Relative Volume:
0.81
시가총액:
$4.75B
수익:
$144.75M
순이익/손실:
$-53.89M
주가수익비율:
-22.28
EPS:
-3.96
순현금흐름:
$-42.88M
1주 성능:
-17.19%
1개월 성능:
-8.92%
6개월 성능:
+64.53%
1년 성능:
+59.79%
1일 변동 폭
$87.02
$89.84
1주일 범위
$87.02
$107.37
52주 변동 폭
$46.42
$107.37
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ACLX | 88.22 | 4.75B | 144.75M | -53.89M | -42.88M | -3.96 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com
Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com
arcellx director Kavita Patel sells $159,495 in stock - Investing.com
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Yahoo Finance
FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com
arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa
Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com
arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com
Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK
US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World
Objective long/short (ACLX) Report - Stock Traders Daily
Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World
Analyst Expectations For Arcellx's Future - Benzinga
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World
Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK
HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat
HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World
Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World
Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India
Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World
Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance
How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN
ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - Citeline
Arcellx stock target increased, rating held on positive trial data - Investing.com
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $100.00 - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $106.00 at Morgan Stanley - MarketBeat
Robert W. Baird Issues Positive Forecast for Arcellx (NASDAQ:ACLX) Stock Price - MarketBeat
HC Wainwright Increases Arcellx (NASDAQ:ACLX) Price Target to $95.00 - MarketBeat
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma - BioSpace
Arcellx shares target upgraded, maintains buy on positive trial data By Investing.com - Investing.com South Africa
Arcellx stock target increased, rating held on positive trial data By Investing.com - Investing.com UK
Navigating 7 Analyst Ratings For Arcellx - Benzinga
Arcellx to present positive data on multiple myeloma treatments - PharmaTimes
BofA raises Arcellx price target to $100 on positive data By Investing.com - Investing.com South Africa
BofA raises Arcellx price target to $100 on positive data - Investing.com
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):